Discovery of MK-3207: A highly potent, orally bioavailable CGRP receptor antagonist

ACS Medicinal Chemistry Letters

Volumn 1, Issue 1, 2010, Pages 24-29

  Bell, Ian M ^a   Gallicchio, Steven N ^a   Wood, Michael R ^a   Quigley, Amy G ^a   Stump, Craig A ^a   Zartman, C Blair ^a   Fay, John F ^a   Li, Chi Chung ^a   Lynch, Joseph J ^a   Moore, Eric L ^a   Mosser, Scott D ^a   Prueksaritanont, Thomayant ^a   Regan, Christopher P ^a   Roller, Shane ^a   Salvatore, Christopher A ^a   Kane, Stefanie A ^a   Vacca, Joseph P ^a   Selnick, Harold G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

calcitonin gene related peptide; MK 3207; pharmacokinetics; receptor antagonist

Indexed keywords

2 [8 (3,5 DIFLUOROPHENYL) 10 OXO 6,9 DIAZASPIRO[4.5]DEC 9 YL] N [2' OXO 1,1',2',3 TETRAHYDROSPIRO[INDENE 2,3' PYRROLO[2,3 B]PYRIDIN] 5 YL]ACETAMIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MK 3207; OLCEGEPANT; PIPERAZINE; TELCAGEPANT; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

EID: 77953425030     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml900016y     Document Type: Article

References (24)

1. Goadsby, P. J.; Lipton, R. B.; Ferrari, M. D. Migraine-current understanding and treatment N. Engl. J. Med. 2002, 346, 257-270
2. Tfelt-Hansen, P.; De Vries, P.; Saxena, P. R. Triptans in Migraine Drugs 2000, 60, 1259-1287
3. 1B/1D agonists) in the acute treatment of migraine Headache 2004, 44, 414-425
4. van Rossum, D.; Hanisch, U.-K.; Quirion, R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors Neurosci. Biobehav. Rev. 1997, 21, 649-678
5. Recober, A.; Russo, A. F. Calcitonin gene-related peptide: An update on the biology Curr. Opin. Neurol. 2009, 22, 241-246
6. Durham, P. L. Inhibition of calcitonin gene-related peptide function: A promising strategy for treating migraine Headache 2008, 48, 1269-1275
7. Brain, S. D.; Grant, A. D. Vascular actions of calcitonin gene-related peptide and adrenomedullin Physiol. Rev. 2004, 84, 903-934
8. Petersen, K. A.; Birk, S.; Lassen, L. H.; Kruuse, C.; Jonassen, O.; Lesko, L.; Olesen, J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers Cephalalgia 2005, 25, 139-147
9. 2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1 H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l -lysyl]-4-(4- pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine J. Med. Chem. 2005, 48, 5921-5931
10. Olesen, J.; Diener, H.-C.; Husstedt, I. W.; Goadsby, P. J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L. M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N. Engl. J. Med. 2004, 350, 1104-1110
11. Paone, D. V.; Shaw, A. W.; Nguyen, D. N.; Burgey, C. S.; Deng, J. Z.; Kane, S. A.; Koblan, K. S.; Salvatore, C. A.; Mosser, S. D.; Johnston, V. K.; Wong, B. K.; Miller-Stein, C. M.; Hershey, J. C.; Graham, S. L.; Vacca, J. P.; Williams, T. M. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: Discovery of N -[(3 R,6 S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1 H -imidazo[4,5- b ]pyridine-1-yl)piperidine-1-carboxamide (MK-0974) J. Med. Chem. 2007, 50, 5564-5567
12. Ho, T. W.; Ferrari, M. D.; Dodick, D. W.; Galet, V.; Kost, J.; Fan, X.; Leibensperger, H.; Froman, S.; Assaid, C.; Lines, C.; Koppen, H.; Winner, P. K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomized, placebo-controlled, parallel-treatment trial Lancet 2008, 372, 2115-2123
13. Tepper, S. J.; Stillman, M. J. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine Headache 2008, 48, 1259-1268
14. Williams, T. M.; Burgey, C. S.; Salvatore, C. A. Calcitonin gene-related peptide antagonists for the treatment of migraine Prog. Med. Chem. 2009, 47, 1-35
15. Bell, I. M.; Bednar, R. A.; Fay, J. F.; Gallicchio, S. N.; Hochman, J. H.; McMasters, D. R.; Miller-Stein, C.; Moore, E. L.; Mosser, S. D.; Pudvah, N. T.; Quigley, A. G.; Salvatore, C. A.; Stump, C. A.; Theberge, C. R.; Wong, B. K.; Zartman, C. B.; Zhang, X.-F.; Kane, S. A.; Graham, S. L.; Vacca, J. P.; Williams, T. M. Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 6165-6169
16. Wood, M. R.; Schirripa, K. M.; Kim, J. J.; Quigley, A. G.; Stump, C. A.; Bell, I. M.; Bednar, R. A.; Fay, J. F.; Bruno, J. G.; Moore, E. L.; Mosser, S. D.; Roller, S.; Salvatore, C. A.; Kane, S. A.; Vacca, J. P.; Selnick, H. G. Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility Bioorg. Med. Chem. Lett. 2009, 19, 5787-5790
17. Salvatore, C. A.; Hershey, J. C.; Corcoran, H. A.; Fay, J. F.; Johnston, V. K.; Moore, E. L.; Mosser, S. D.; Burgey, C. S.; Paone, D. V.; Shaw, A. W.; Graham, S. L.; Vacca, J. P.; Williams, T. M.; Koblan, K. S.; Kane, S. A. Pharmacological characterization of MK-0974 [ N -[(3 R,6 S)-6-(2,3- difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1 H -imidazo[4,5- b ]pyridine-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine J. Pharmacol. Exp. Ther. 2008, 324, 416-421
18. Roller, S.; Cui, D.; Laspina, C.; Miller-Stein, C.; Rowe, J.; Wong, B.; Prueksaritanont, T. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin gene-related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences Xenobiotica 2009, 39, 33-45
19. Wood, M. R.; Bell, I. M.; Selnick, H. G.; Stump, C. A.; Gallicchio, S. N.; Zartman, C. B. WO 2008/020902.
20. Gallicchio, S. N.; Bell, I. M. Convenient synthesis of 1,3-substituted-6-phenylpiperazin-2-ones Tetrahedron Lett. 2009, 50, 3817-3819
21. Stump, C. A.; Bell, I. M.; Bednar, R. A.; Bruno, J. G.; Fay, J. F.; Gallicchio, S. N.; Johnston, V. K.; Moore, E. L.; Mosser, S. D.; Quigley, A. G.; Salvatore, C. A.; Theberge, C. R.; Zartman, C. B.; Zhang, X.-F.; Kane, S. A.; Graham, S. L.; Vacca, J. P.; Williams, T. M. The discovery of highly potent CGRP receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 214-217
22. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technol. 2004, 1, 337-341
23. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623
24. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption J. Pharm. Sci. 1999, 88, 807-814